Chk2 inhibitors (depicted in Figure S2) have been envisioned as attractive therapeutic agents for their potential at sensitizing cancer cells to DNA-damaging agents and their ability to protect normal cells against DNA damage-induced apoptosis [93,122,123,124]. This evidence concerns the gene CHEK2 and cancer.